Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | — | 3 | 1 | — | — | — | 4 |
Glioma | D005910 | EFO_0000520 | — | 3 | 1 | — | — | — | 4 |
Gliosarcoma | D018316 | — | — | 2 | 1 | — | — | — | 3 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
Nervous system diseases | D009422 | — | G00-G99 | 1 | 1 | — | — | — | 2 |
Neoplasms by histologic type | D009370 | — | — | — | 1 | — | — | — | 1 |
Nerve tissue neoplasms | D009380 | — | — | — | 1 | — | — | — | 1 |
Primitive neuroectodermal tumors | D018242 | — | — | — | 1 | — | — | — | 1 |
Neuroepithelial neoplasms | D018302 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 2 | — | — | — | — | 2 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Neoadjuvant therapy | D020360 | — | — | 1 | — | — | — | — | 1 |
Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
Brain stem neoplasms | D020295 | EFO_1001767 | — | 1 | — | — | — | — | 1 |
Central nervous system diseases | D002493 | HP_0002011 | G96.9 | 1 | — | — | — | — | 1 |
Drug common name | TASADENOTUREV |
INN | tasadenoturev |
Description | Tasadenoturev is an unknown pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Unknown |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990045 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 79ME7DT193 (ChemIDplus, GSRS) |